Strategic Alliances

Partnership is becoming increasingly important in the pharmaceutical environment, both in terms of strategy for the development and the commercialization of novel drugs and of international growth in the global arena. For this reason Chiesi is currently nourishing relationships with existing partners with even more attention than in the past and is dedicating increasing energies to the defi nition of new agreements. Chiesi is recognized as an innovative and reliable company and is determined to confi rm its reputation to be a partner of choice based on performance and loyalty.
During 2006 Chiesi established an important agreement with UCB to co-market Foster® in Germany and further opportunities concerning this product are under evaluation.

Chiesi consolidated its partnership with Novartis for the distribution of formoterol Modulite® in a number of countries, as well as the cooperation with Vernalis for the development of a carbidopa + melevodopa combination for Parkinson’s disease as well as for CHF 3381 for neuropathic pain. In line with Chiesi’s traditions, licensing activities are not limited to commercialized products: the acquisition of the orphan drug designation for caffeine-citrate is one further important step for the development of drugs indicated for the treatment of premature neonates affected by respiratory problems.
In the course of the year support to affi liates in the research of business partners was an important part of the contribution provided by Corporate Development to the Group: this activity is currently disclosing promising opportunities on a local basis.